Pharmacology of Alzheimer's disease: appraisal and prospects.
Dement Geriatr Cogn Disord
; 19(5-6): 229-45, 2005.
Article
en En
| MEDLINE
| ID: mdl-15767760
Ten years after the introduction of the first drug, tacrine, in the treatment of Alzheimer's disease, it seems appropriate to re-appraise the pharmacological processes of innovation in the research field of dementia. The aim of this review is to pinpoint concrete improvements achieved in this field, regarding experimental methods and clinical evaluation of the compounds, as well as the neurochemistry of the disease and cellular targets to consider in priority. This review deals with this objective in three parts: (1) assessment of current therapeutics, (2) discussion of the experimental models and clinical practices and (3) prospective drugs of the future. The implementation of considered strategies will require the involvement and close cooperation between political decisions, pharmaceutical companies and the scientific community.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Nootrópicos
/
Enfermedad de Alzheimer
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Dement Geriatr Cogn Disord
Asunto de la revista:
GERIATRIA
/
NEUROLOGIA
/
PSIQUIATRIA
Año:
2005
Tipo del documento:
Article
País de afiliación:
Francia
Pais de publicación:
Suiza